$290 Million is the total value of Artia Global Partners LP's 34 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 75.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Sell | BIOGEN INC | $14,890,534 | -33.1% | 52,275 | -34.7% | 5.13% | -37.5% |
| ISEE | Sell | IVERIC BIO INC | $9,632,832 | -2.1% | 244,861 | -39.5% | 3.32% | -8.7% |
| LLY | Sell | LILLY ELI & CO | $7,594,193 | -17.9% | 16,193 | -39.9% | 2.62% | -23.4% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $6,801,346 | -41.0% | 78,465 | -33.8% | 2.34% | -44.9% |
| LRMR | Exit | LARIMAR THERAPEUTICS INC | $0 | – | -38,057 | -100.0% | -0.06% | – |
| LEGN | Exit | LEGEND BIOTECH CORPsponsored ads | $0 | – | -5,000 | -100.0% | -0.09% | – |
| Exit | AMYLYX PHARMACEUTICALS INC | $0 | – | -8,339 | -100.0% | -0.09% | – | |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -256,800 | -100.0% | -0.14% | – |
| Exit | ALTIMMUNE INCcall | $0 | – | -100,000 | -100.0% | -0.16% | – | |
| FGEN | Exit | FIBROGEN INC | $0 | – | -51,795 | -100.0% | -0.36% | – |
| VRNA | Exit | VERONA PHARMA PLCsponsored ads | $0 | – | -90,451 | -100.0% | -0.67% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcl a | $0 | – | -40,000 | -100.0% | -1.34% | – |
| Exit | KARUNA THERAPEUTICS INCput | $0 | – | -30,000 | -100.0% | -2.01% | – | |
| Exit | NOVO-NORDISK A Scall | $0 | – | -50,000 | -100.0% | -2.94% | – | |
| Exit | SAREPTA THERAPEUTICS INCcall | $0 | – | -60,000 | -100.0% | -3.06% | – | |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -88,831 | -100.0% | -5.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVO-NORDISK A S | 4 | Q3 2023 | 25.8% |
| MERCK & CO INC | 4 | Q3 2023 | 14.1% |
| ARGENX SE | 4 | Q3 2023 | 12.3% |
| LILLY ELI & CO | 4 | Q3 2023 | 14.5% |
| ABBVIE INC | 4 | Q3 2023 | 5.6% |
| ASTRAZENECA PLC | 4 | Q3 2023 | 5.4% |
| SEAGEN INC | 4 | Q3 2023 | 4.5% |
| BIOMARIN PHARMACEUTICAL INC | 4 | Q3 2023 | 4.3% |
| NEUROCRINE BIOSCIENCES INC | 4 | Q3 2023 | 2.1% |
| VERTEX PHARMACEUTICALS INC | 4 | Q3 2023 | 2.6% |
View Artia Global Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
View Artia Global Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.